Author + information
- Received October 24, 2019
- Revision received December 2, 2019
- Accepted December 17, 2019
- Published online May 4, 2020.
- Mohamed Abdel-Wahab, MDa,∗ (, )@Mo_A_W,
- Martin Landt, MDb,
- Franz-Josef Neumann, MDc,
- Steffen Massberg, MDd,
- Christian Frerker, MDe,
- Thomas Kurz, MDf,
- Jatinderjit Kaur, MDb,
- Ralph Toelg, MDb,
- Susanne Sachse, MTAb,
- David Jochheim, MDd,
- Ulrich Schäfer, MDe,
- Mohamed El-Mawardy, MDg,
- Derek R. Robinson, DPhilh,
- Gert Richardt, MDb,
- for the CHOICE Investigators
- aHeart Center Leipzig at the University of Leipzig, Leipzig, Germany
- bHeart Center, Segeberger Kliniken, Bad Segeberg, Germany
- cUniversity Heart Center Freiburg-Bad Krozingen, Bad Krozingen, Germany
- dMunich University Clinic, Munich, Germany
- eCardiology Department, Asklepios Clinic St. Georg, Hamburg, Germany
- fCardiology Department, Lübeck University Hospital, Lübeck, Germany
- gCardiology Department, Vivantes Wenckebach Hospital, Berlin, Germany
- hMathematics Department, University of Sussex, Brighton, England
- ↵∗Address for correspondence:
Dr. Mohamed Abdel-Wahab, Heart Center Leipzig at the University of Leipzig, Strümpellstraße 39, 04289 Leipzig, Germany.
Objectives The purpose of this study was to evaluate clinical and echocardiographic outcome data of the CHOICE (Randomized Comparison of Transcatheter Heart Valves in High Risk Patients with Severe Aortic Stenosis: Medtronic CoreValve Versus Edwards SAPIEN XT) trial at 5 years.
Background The CHOICE trial was designed to compare device performance of a balloon-expandable (BE) transcatheter heart valve (THV) versus a self-expanding (SE) THV.
Methods The CHOICE trial is an investigator-initiated trial that randomized 241 high-risk patients with severe symptomatic aortic stenosis and an anatomy suitable for treatment with both BE and SE THVs to transfemoral transcatheter aortic valve replacement with either device. The primary endpoint was device success. Patients were followed up to 5 years, with assessment of clinical outcomes, and echocardiographic evaluation of valve function and THV durability.
Results After 5 years, there were no statistically significant differences between BE and SE valves in the cumulative incidence of death from any cause (53.4% vs. 47.6%; p = 0.38), death from cardiovascular causes (31.6% vs. 21.5%; p = 0.12), all strokes (17.5% vs. 16.5%; p = 0.73), and repeat hospitalization for heart failure (28.9% vs. 22.5%; p = 0.75). SE patients had larger prosthetic valve area (1.6 ± 0.5 cm2 vs. 1.9 ± 0.5 cm2; p = 0.02) with a lower mean transprosthetic gradient (12.2 ± 8.7 mm Hg vs. 6.9 ± 2.7 mm Hg; p = 0.001) at 5 years. No differences were observed in the rates of paravalvular regurgitation. Clinical valve thrombosis occurred in 7 BE patients (7.3%) and 1 SE patient (0.8%; p = 0.06), and moderate or severe structural valve deterioration in 6 BE patients (6.6%) and no SE patient (0%; p = 0.018). The rate of bioprosthetic valve failure was low and not significantly different between both groups (4.1% vs. 3.4%; p = 0.63).
Conclusions Five-year follow-up of patients in the CHOICE trial revealed clinical outcomes after transfemoral transcatheter aortic valve replacement with early-generation BE and SE valves that were not statistically significantly different, with limited statistical power. Forward flow hemodynamics were significantly better with the SE valve. Moderate or severe structural valve deterioration was uncommon but occurred more frequently with the BE valve. (A Comparison of Transcatheter Heart Valves in High Risk Patients With Severe Aortic Stenosis: The CHOICE Trial [CHOICE]; NCT01645202)
Funded by the Heart Center, Segeberger Kliniken GmbH, Bad Segeberg, Germany. Dr. Abdel-Wahab has been a proctor and consultant for Boston Scientific and Medtronic. Dr. Neumann has received institutional research grants, consultancy fees, and speaker honoraria from Edwards Lifesciences, Daiichi-Sankyo, AstraZeneca, Sanofi, Bayer, The Medicines Company, Bristol-Myers Squibb, Novartis, Roche, Boston Scientific, Biotronik, Ferrer, and Medtronic. Dr. Frerker has received speaker honoraria from Edwards Lifesciences. Dr. Richardt has received an institutional research grant from Biotronik, St. Jude Medical, and Medtronic; and is an advisory board member for Abbott Vascular and Boston Scientific. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.
The authors attest they are in compliance with human studies committees and animal welfare regulations of the authors’ institutions and Food and Drug Administration guidelines, including patient consent where appropriate. For more information, visit the JACC: Cardiovascular Interventions author instructions page.
- Received October 24, 2019.
- Revision received December 2, 2019.
- Accepted December 17, 2019.
- 2020 American College of Cardiology Foundation
This article requires a subscription or purchase to view the full text. If you are a subscriber or member, click Login or the Subscribe link (top menu above) to access this article.